We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
International Accord Gives US Firm Rights to Stem Cell Liver Cure
News

International Accord Gives US Firm Rights to Stem Cell Liver Cure

International Accord Gives US Firm Rights to Stem Cell Liver Cure
News

International Accord Gives US Firm Rights to Stem Cell Liver Cure

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "International Accord Gives US Firm Rights to Stem Cell Liver Cure "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem Cell RegenCo and IIBM have entered into an exclusive joint venture giving liver damage patients a crucial alternative to a dangerous and uncertain liver transplant.

IIBM is headed by Gennady T. Sukhikh, MD, who, according to a Google computer search, is one of the world's foremost stem cell research specialists.

The focus of the agreement is to extend IIBM's Stem Cell Liver Regeneration (SCLR) procedure to the western world where due to the ban on embryonic stem cell research none currently exists.

A liver transplant is now the only treatment for acute and chronic liver failure.

The problems with these transplants are threefold: (1) there is a severe shortage of donor organs and thousands of patients die each year while awaiting an available donor liver; (2) the very great possibility the patient's body will reject the foreign liver; (3) even if the liver is not rejected the patients spend the rest of their lives on immuno-suppression drugs.

These drugs leave liver recipients open to infection and increase the risk of heart disease or cancer later in life. The cost of such drugs alone is $10,000 per year for life.

With the IIBM developed, non-invasive stem cell regeneration procedure, none of the above factors apply - no rejection possibilities, no immuno- suppression drugs or costs.

Shortly after the procedure, the patient will have a regenerated liver that replaces the old Hep B, C, cirrhosis or other diseased liver.

As confirmed by a multitude of clinical trials this procedure is effective and safe even in extreme emergencies such as end-stage liver disease.

Due to its non-surgical nature, it is particularly effective for treatment of children's liver problems.

Advertisement